26 / 32
Page 56
Volume 08
Clinical Pharmacology & Biopharmaceutics
ISSN: 2167-065X
Pharmacology 2019
World Heart Congress 2019
August 19-20, 2019
JOINT EVENT
conferenceseries
.com
August 19-20, 2019 Vienna, Austria
&
7
th
World Heart Congress
24
th
World Congress on
Pharmacology
Aprospective cross-sectional study to evaluate the economic burden of patients diagnosed with depression
in a tertiary care hospital
Femina Dawer
and
Dinesh Dhodi
Grant Govt. Medical College and Sir J.J Hospital, India
Statement of the Problem
: Depression is a common psychiatric disorder having important medical, social and
psychological consequences. It is a disorder associated with enormous burden in terms of reduced quality of life as
well as direct and indirect costs. It is a well -known fact that the majority of the economic burden of depression results
from non- depression expenditures. Hence, the study was undertaken to evaluate economic burden of depression.
The purpose of this study is to evaluate the cost off depression in terms of direct and indirect costs.
Methodology & Theoretical Orientation
: 150 patients diagnosed with depression attending psychiatry OPD at Sir
J.J. Group of Hospitals, Mumbai, fulfilling the inclusion criteria were explained about the study. Written informed
consent were taken. Direct and Indirect costs were recorded in Structured Case Record Forms by interviewing the
patients. Cost driving factors were identified.
Findings
: Total annual direct cost was 6,378.16 INR while annual Indirect Cost was INR 16,860. Annual cost of
Depression was 1NR 23,238.16/331.97 USD per patient. Total cost was 16.30% of per capita GDP 2018 among
Depression patients in India. The annual economic burden of depression in India is 1.2% of GNP of India.
Conclusion & Significance
: The indirect cost was almost thrice the direct costs. Hospitalisation cost and loss of
working days due to depression was contributed the most to the direct costs and indirect costs respectively. Economic
burden of Depression is found out to be 16.30% of per capita GDP in year 2018-2019.
Recommendation
: Multi-centric studies to evaluate pharmaco-economic burden across the country and analyse the
burden of the disease. Thus, shifting the approach to prevention rather treatment reducing the economic burden of
the illness.
Recent Publications:
1.
Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology
of DSM-IV major depressive episode. BMC Med 2011; 9:90.
2.
Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe—a critical review and appraisal of 27
studies. Eur Neuropsychopharmacol. 2005;15: 357-376
3.
Karampampa K, Borgström F, Jönsson B. Economic burden of depression of society. Medicographia.
2011;33(2):163-8.
4.
Luppa M, Heinrich S, Angermeyer MC, Konig HH, Riedel-Heller SG. Cost-ofillness studies of depression: a
systematic review. J Affect Disord. 2007;98: 29-43
5.
Sarkar S, Mathan K, Sakey S, Shaik S, Subramanian K, Kattimani S. Cost-of-treatment of clinically stable
severe mental lilnesses in India. Indian Journal of Social Psychiatry. 2017 Jul 1;33(3):262.
6.
Sobocki P, EkmanM, AgrenH, RunesonB, JonssonB.Themission is remission: health economic consequences
of achieving full remission with antidepressant treatment for depression. Int J Clin Pract. 2006; 60:791-798.
Femina Dawer et al., Clin Pharmacol Biopharm, Volume 08